| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 147.44 | 41.2% |
| Total Income | 147.44 | 41.2% |
| Expenditure | 153.95 | 34.7% |
| PBT | -2.49 | 87.3% |
| Net Profit | -2.49 | 87.3% |
| OPM | -4.42% | 5.08pp |
| NPM | -1.69% | 17.07pp |
| EPS | -0.02 | 90.5% |
The Oncology Institute Reports Q1 2026 Revenue Up 41.2% YOY
08 May 2026 · 8 May, 1:51 am
Summary
The Oncology Institute reported a strong start to 2026 with a 41.2% increase in consolidated revenue, reaching $147.4 million. This growth was driven by strong capitated revenue and record performance in the pharmacy business. The company's net loss improved to $2.5 million compared to $19.6 million in the prior year. The company is reaffirming its guidance for 2026 revenue and adjusted EBITDA, expressing confidence in achieving sustainable profitability over the long term.
Key Highlights
- 1
The Oncology Institute's consolidated revenue of $147.4 million increased by 41.2% compared to $104.4 million in the prior year quarter.
- 2
Gross profit for the quarter was $23.3 million, reflecting a 35.2% increase year-over-year.
- 3
The company reported a net loss of $2.5 million, an improvement compared to a net loss of $19.6 million in the same quarter of the previous year.
- 4
Basic and diluted loss per share improved to $(0.02) compared to $(0.21) in the prior year quarter.
- 5
Adjusted EBITDA was $(2.4) million, an improvement from $(5.1) million in the first quarter of the previous year.
- 6
Specialty Pharmacy revenue increased by 78% due to record Part D fills.
- 7
The company saved approximately $2 million in Medicare spending as part of the CMS Enhancing Oncology Model performance program.
Management Comments
Daniel Virnich
The first quarter of 2026 was a strong start to the year for TOI, delivering 41% year over year revenue growth, driven in part by strong capitated revenue growth and a record performance in our pharmacy business. We made meaningful progress on several fronts, including in Florida, where we reached profitability, marking an important milestone that reflects the maturation of our capitated relationships in the state, which is a proof point of our model. Our provider portal, which is designed to underscore our commitment to high quality patient care, strengthen provider engagement, and drive continued adherence to our clinical pathways and quality metrics, is preparing for launch this summer. Looking ahead, we are focused on building on the momentum we have coming out of this quarter, are reaffirming our guidance for 2026 revenue and adjusted EBITDA, and feel confident in our ability to execute sustainable profitability over the long term.
Informational and educational content only. Not investment advice.